Michael Fuchs, Anne Sophie Jacob, Helen Kaul, Carsten Kobe, Georg Kuhnert, Thomas Pabst, Richard Greil, Paul J Bröckelmann, Max S Topp, Marianne Just, Bernd Hertenstein, Martin Soekler, Martin Vogelhuber, Josée M Zijlstra, Ulrich Bernd Keller, Stefan W Krause, Ulrich Dührsen, Julia Meissner, Andreas Viardot, Hans-Theodor Eich, Christian Baues, Volker Diehl, Andreas Rosenwald, Ina Buehnen, Bastian von Tresckow, Markus Dietlein, Peter Borchmann, Andreas Engert, Dennis A Eichenauer
The primary analysis of the GHSG HD16 trial indicated a significant loss of tumor control with PET-guided omission of radiotherapy (RT) in patients with early-stage favorable Hodgkin lymphoma (HL). This analysis reports long-term outcomes. Overall, 1150 patients aged 18-75 years with newly diagnosed early-stage favorable HL were randomized between standard combined-modality treatment (CMT) (2x ABVD followed by PET/CT [PET-2] and 20 Gy involved-field RT) and PET-2-guided treatment omitting RT in case of PET-2 negativity (Deauville score [DS] < 3)...
January 2024: Leukemia